{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 376276316
| IUPAC_name = (6-Amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid)
| image = Neridronic acid.png
| width = 150

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 79778-41-9
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 71237
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8U27U3RIN4
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 64372

<!--Chemical data-->
| chemical_formula =  
| C=6 | H=17 | N=1 | O=7 | P=2 
| molecular_weight = 277.14 g/mol
|  smiles = C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PUUSSSIBPPTKTP-UHFFFAOYSA-N
}}

'''Neridronic acid''' ([[International Nonproprietary Name|INN]]; the [[anion]] is called neridronate) is a [[bisphosphonate]]. In Italy it is used to treat [[Osteogenesis imperfecta]] and [[Paget's disease of bone]].<ref>{{cite journal | pmid = 19761412 | doi=10.1517/17425250903029190 | volume=5 | title=Neridronic acid for the treatment of bone metabolic diseases | journal=Expert Opin Drug Metab Toxicol | pages=1305-11 | vauthors=Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S}}</ref>

A 2013 clinical trial suggests CRPS Type I ([[Complex regional pain syndrome]]) responds to treatment with intravenous neridronate.<ref name="Varenna 2013 534–42">{{cite journal  |vauthors=Varenna M, Adami S, Rossini M, etal |title=Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study |journal=Rheumatology |volume=52 |issue=3 |pages=534–42 |date=March 2013  |pmid=23204550 |doi=10.1093/rheumatology/kes312}}</ref>

== References ==
{{Reflist}}
{{Bisphosphonates}}

[[Category:Bisphosphonates]]


{{musculoskeletal-drug-stub}}